Inclusion Criteria:

          -  Participants must have histologically confirmed clinical stage II or III ERPR- HER2+
             (per CAP criteria) invasive carcinoma of the breast

          -  Medically and surgically appropriate to undergo neoadjuvant chemotherapy with TCH-P
             Taxotere (docetaxel), Carboplatin, Herceptin (trastuzumab), Perjeta (pertuzumab)
             regimen followed by standard of care local therapy as determined by their treating
             physician

          -  Age ≥18 years.

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than 2

          -  Patients must have normal organ and marrow function as defined below:

               -  leukocytes ≥3,000/μL

               -  absolute neutrophil count ≥1,500/μL

               -  platelets ≥100,000/μL

               -  total bilirubin within normal institutional limits

               -  AST(SGOT)/ALT(SGPT) less than or equal to 2.5 X institutional upper limit of
                  normal

               -  creatinine within normal institutional limits - OR -

               -  creatinine clearance ≥60 mL/min/1.73 m^2 for patients with creatinine levels
                  above institutional normal

          -  Cardiac ejection fraction within institutional normal limits by either MUGA or ECHO at
             baseline.

          -  Women of child-bearing potential and their male partners must agree to use adequate
             contraception (hormonal or barrier method of birth control; abstinence) prior to study
             entry and for the duration of study participation. Should a woman become pregnant or
             suspect she is pregnant while participating in this study, she should inform her
             treating physician immediately. Sexually active male participants should use a barrier
             method or exercise abstinence during chemotherapy administration until surgery.

          -  Ability to understand and the willingness to sign a written informed consent document.

        Exclusion Criteria:

          -  Patients with inflammatory breast cancer, widespread locally advanced unresectable
             disease involving the chest wall/nodal basins in which a curative surgical resection
             cannot be performed, or those in whom de novo metastatic disease is suspected or
             confirmed

          -  May not be receiving any other investigational agents for the treatment of their
             breast cancer.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to the study vaccine components and any of the chemotherapy drugs
             (docetaxel, carboplatin, trastuzumab, pertuzumab)

          -  Unwilling or unable to undergo an apheresis for production of their vaccine

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Women who are pregnant or breastfeeding

          -  Known congenital or acquired immune deficiency (including those patients who require
             systemic immunosuppressant drugs for autoimmune disease or organ transplant).

          -  Pre-existing peripheral neuropathy that would limit treatment with taxanes and
             platinum agents